What is ReachBio?
ReachBio Research Labs operates at the intersection of advanced biotechnology and pharmaceutical development. The company provides essential primary cell biology services and products, with a distinct focus on blood and bone marrow systems. Their portfolio supports a wide array of scientific disciplines, including hematology, immunology, and toxicology. By serving as a strategic partner for organizations involved in basic research and drug discovery, ReachBio facilitates the translation of scientific concepts into viable clinical applications. Their commitment to high-quality, primary cell-based assays makes them a cornerstone for researchers focused on immuno-oncology and hematological disease pathways.
How much funding has ReachBio raised?
ReachBio has raised a total of $187K across 1 funding round:
Debt
$187K
Debt (2021): $187K with participation from PPP
Key Investors in ReachBio
PPP
Public-Private Partnership
What's next for ReachBio?
Following this late-stage strategic investment, ReachBio is poised to scale its infrastructure to meet the growing demand for specialized contract research services. The company's roadmap likely involves enhancing its proprietary cell-based assay platforms and expanding its reach within the global life science community. As the pharmaceutical industry continues to prioritize precision medicine and targeted therapies, ReachBio's focus on primary cell systems provides a competitive advantage. Future growth will likely center on deepening its involvement in clinical drug development programs and potentially diversifying its product suite to address emerging challenges in immunology and oncology research. This capital deployment strategy is designed to sustain long-term value creation for stakeholders while maintaining the company's reputation for scientific rigor.
See full ReachBio company page
